A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response

Bing Feng; Li Tang

doi:10.1002/ctm2.70154

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70154 DOI: 10.1002/ctm2.70154

COMMENTARY

A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response

Bing Feng ¹^,²^,³^,^†
, Li Tang ¹^,²^,^†

Author information +

History +

PDF

Keywords

cancer immunotherapy / curative response / Type 2 immunity

Cite this article

Download citation ▾

Bing Feng, Li Tang. A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response. Clinical and Translational Medicine, 2025, 15(1): e70154 DOI:10.1002/ctm2.70154

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.